Nanni, Cristina http://orcid.org/0000-0003-2000-1599
Zanoni, Lucia
Bach-Gansmo, Tore
Minn, Heikki
Willoch, Frode
Bogsrud, Trond Velde
Edward, Ephraim Parent
Savir-Baruch, Bital
Teoh, Eugene
Ingram, Fenton
Fanti, Stefano
Schuster, David M.
Article History
Received: 25 October 2019
Accepted: 11 November 2019
First Online: 11 December 2019
Compliance with ethical standards
:
: Cristina Nanni provided consultancy for Blue Earth Diagnostics Ltd. 2018–1019. She was Principal Investigator of the project entitled <i>ANTI-3-18F-FACBC (anti1-amino-3-18F-fluorocyclobutane-1-carboxylic acid) in comparison to 11c-choline PET/CT in the evaluation of patients with prostate cancer radically treated and with rising PSA</i>, "Programma di ricerca Regione- Università 2013-Area 1 "Ricerca Innovativa", Bando "Alessandro Liberati"-Giovani Ricercatori".Lucia Zanoni had a scientific-only relationship with the company “Blue Earth Diagnostics Ltd.” as Medical Staff of the Sponsored Study BED001 (118/2014/O/Oss), (no financial relationship, no compensation received). Lucia Zanoni was Principal Investigator of the project entitled “18F-FACBC PET/CT for staging high risk prostate cancer” funded by “Programma di ricerca Regione- Università 2013-Area 1 “Ricerca Innovativa”, Bando “Alessandro Liberati-Giovani Ricercatori”. In the context of this project, Lucia Zanoni received a granted 1-year SSN contract as nuclear medicine project manager (both scientific and financial relationship)Tore Bach-Gansmo is a consultant for BED, and the hospital has received research funding from BED.Heikki Minn institution (Turku University Hospital) has a research contract with Blue Earth Diagnostics (not related to fluciclovine).Frode Willoch has provided consultancy for Blue Earth Diagnostics Ltd. 2016–2017.Trond Velde Bogsrud received research funding from Blue Earth Diagnostics Ltd, marketer of 18F-fluciclovine (Axumin), to Oslo University Hospital, Oslo, Norway, for clinical studies using 18F-fluciclovine PET/CT in prostate cancer performed together with Bach-Gansmo T.Ephraim Parent participates in research funded in part by Blue Earth Diagnostics.Bital Savir-Baruch had grant support by Blue Earth Diagnostics.Dr. Eugene Teoh was a consultant to Blue Earth Diagnostics and affiliated to Oxford University, at time of contribution to the published work. At time of subsequent publication, Dr. Eugene Teoh is an employee of Blue Earth Diagnostics.Fenton Ingram RT(R), CNMT, PET has no financial or non-financial conflict of interest to declare.Stefano Fanti, with respect to the mentioned paper, declares that he attended an advisory board of Blue Earth Diagnostics in 2014 and in 2015.David Schuster is a Consultant in Syncona, AIM Specialty Health, and participated through the Emory Office of Sponsored Projects in sponsored grants including those funded or partially funded by Blue Earth Diagnostics, Ltd.; Nihon MediPhysics Co, Ltd.; Telix Pharmaceuticals (USA) Inc.; Advanced Accelerator Applications; and FUJIFILM Pharmaceuticals USA, Inc.
: There are no human or animal participants in the study.
: This is a procedural guideline so no informed consent was necessary.